A wide-ranging group of 15 nonprofits, humanitarian aid organizations and other funders plan to open this year’s Clinton ...

Sanofi has stayed out of the obesity drug development bonanza, taking a wait-and-see approach while keeping an eye on ...

Pharma stocks have been on quite a nice run over the past year. A number of new catalysts have revitalized this sector, which ...

Shares of Ventyx Biosciences rose more than 20% in premarket trading after the clinical-stage biopharmaceutical company said it would receive a $27 million from France's Sanofi.

The FDA approved Sanofi's Sarclisa (isatuximab) in combination with VRd as a first-line treatment for newly diagnosed ...

In connection with the equity investment, the Company has agreed to grant Sanofi an exclusive right of first negotiation with respect to certain VTX3232 program rights.

Barclays analyst Emily Field maintained a Buy rating on Sanofi (SNYNF – Research Report) today and set a price target of €120.00. The ...